Researchers at Israel’s Technion have developed an AI system that identified 77 approved cancer nano-therapies that can chemically self-assemble in nearly 2,000 combinations to be far more effective, with less side-effects. They proved their system, combining bortezomib-cabozantinib to treat head/neck … Continue reading →

GranaGard Nano Omega 5, made by Israel’s Granalix Biotechnologies, is now available in Israel and online. The nano-engineered high antioxidant supplement from pomegranate oil (see previously) improves cognitive function in Multiple Sclerosis patients and will be tested on dementia patients. … Continue reading →

Israel’s Limaca Medical (see here previously) has received US FDA approval for its Precision GI™ Endoscopic Ultrasound (EUS) Biopsy Device. The device automatically obtains biopsies, for diagnosis of pancreatic cancer and other cancers, quicker and safer than current products. https://www.prnewswire.com/il/news-releases/limaca-medical-receives-fda-510k-clearance-for-its-breakthrough-precision-gi-endoscopic-biopsy-device-301923165.html

Israel’s Techsomed (see here previously) has received US FDA approval for its Ablation Treatment Planning and Confirmation Software. VisAble.IO helps guide surgeons using ablation therapy (extreme heat or cold) to destroy tumors. https://www.prnewswire.com/news-releases/techsomed-announces-fda-clearance-for-ablation-treatment-planning-and-confirmation-software-301917800.html

Israel’s Elgan Pharma (see here previously) has been awarded a 2.36 million euros grant by the European Innovation Council. It will support a Phase III study of its ELGN-GL oral insulin-based formulation that helps the development of a preemie’s gastrointestinal … Continue reading →

Israel’s Nasus Pharma (see here previously) has reported positive results from its latest clinical study of its FMXIN002 intranasal Epinephrine powder spray device. It provides a safe and effective rescue for the emergency treatment of life-threatening allergic reactions. https://www.prnewswire.com/news-releases/nasus-pharma-announces-publication-of-its-positive-clinical-results-with-fmxin002-intranasal-powder-epinephrine-spray-in-the-journal-of-allergy-and-clinical-immunology-in-practice-301895372.html https://pubmed.ncbi.nlm.nih.gov/37394178/

Israel’s UroGen Pharma (see here previously) has published positive results from two clinical trials of bladder cancer treatment UGN-102. The therapy can benefit some 80,000 patients. Trial success (65%) was similar to patients who had surgery but with a 55% … Continue reading →